Speed of access getting drugs to market, but then you are actively working to block the less expensive biosimilars and generics to come to market, and that is something we should address.
Maggie Hassan: “Speed of access getting drugs to market, but then you are actively working to block the less expensive biosimilars and…”
Editor's note · Context
Highlighting the contradiction in drug companies' actions regarding market access.
Share
More from Maggie Hassan
As threats at our Northern border continue to evolve, the federal government’s strategy must keep pace.
The Administration’s decision is outrageous; the fight against addiction is hard enough, and the work of first responders and law enforcement will only become more difficult if we defund proven efforts that have saved lives.
The legislation builds on the No Surprises Act by clearly defining what information must be included in these estimates—including facility fees, a provision added at Senator Hassan's request—to help patients avoid unexpected costs.
He will save one of his corrupt campaign donors asking for a pardon, but he won’t lift a finger to save American families a dime on their groceries.





